Preparation evaluation system based on electronic medical record data
By using a formulation evaluation system based on electronic medical record data, combined with assessments of combined medication, safety, and efficacy, the system provides doctors with a scientific basis, solving the problem that existing technologies have failed to effectively evaluate the efficacy and side effects of drug formulations, and improving the scientific rigor and safety of prescriptions.
Patent Information
- Application Number
- CN202410962036.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the current technology, doctors have not been able to effectively combine electronic medical record data to evaluate the efficacy and side effects of drug preparations when prescribing medications.
A formulation evaluation system based on electronic medical record data was designed, including a patient electronic medical record data acquisition module, a formulation evaluation module, a risk assessment module, and a data visualization module. Through combined drug use evaluation, formulation safety evaluation, formulation effectiveness evaluation, and comprehensive evaluation, it provides data support for doctors to prescribe medications.
It enables the evaluation of combined drug use, safety, and efficacy of drug formulations, providing doctors with scientific evidence, reducing the risk of adverse events, and improving the scientific nature and safety of prescriptions.
Smart Images

Figure CN118919097A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of preparation evaluation, and in particular to a preparation evaluation system based on electronic medical record data. Background Art
[0002] Drug preparation research is an important part of pharmaceutical research and an important link in the process of drugs from compounds to products. It not only combines the physicochemical properties and pharmacological activity of drugs and excipients, but also involves the selection of drug dosage forms, drug prescription design, selection of preparation processes and preparation quality assessment, and provides guidance for the industrial production of drug preparations. Therefore, drug preparation research is highly professional and comprehensive.
[0003] With the development of science and technology, Electronic Medical Record (EMR) is a kind of patient medical information that is recorded, stored, managed and used in an electronic way, including medical records, medical images, laboratory test results and other information. It saves, manages, transmits and reproduces digital patient medical records through electronic devices (such as computers, health cards, etc.), replacing handwritten paper medical records. Electronic medical records include not only static medical record information, but also related services provided. It is information about an individual's lifelong health status and medical care behavior managed in an electronic way, involving all process information such as the collection, storage, transmission, processing and utilization of patient information. At present, when existing doctors prescribe, they usually prescribe relevant pharmaceutical preparations based on their experience, and there is no means to evaluate the efficacy and side effects of a certain preparation based on the data of electronic medical records. Summary of the invention
[0004] 1. Technical issues to be resolved
[0005] In view of the deficiencies in the prior art, the present invention provides a preparation evaluation system based on electronic medical record data, which has the advantages of providing data support for preparation evaluation and solves the above-mentioned technical problems.
[0006] (II) Technical solution
[0007] To achieve the above-mentioned object, the present invention provides the following technical solutions: a preparation evaluation system based on electronic medical record data, comprising a patient electronic medical record data collection module, a preparation evaluation module, a risk assessment module and a data visualization module;
[0008] The patient electronic medical record data collection module is used to collect the patient's electronic medical record data, including the patient's disease, drug prescription, medication history and laboratory test results, and the patient electronic variable data collection module sends the collected data to the preparation evaluation module;
[0009] The preparation evaluation module includes a combination drug evaluation unit, a preparation safety evaluation unit, a preparation effectiveness evaluation unit and a comprehensive evaluation unit;
[0010] The combined medication evaluation unit is used to evaluate the interactions between multiple drugs when a patient needs to be treated with multiple drugs. The adverse event rate of the combination drug with preparation q relative to the combination drug without preparation q or the single drug was evaluated by R q,\q and send the evaluation results to the comprehensive evaluation unit;
[0011] The preparation safety assessment unit is used to assess the safety of the preparation by measuring the side effects and allergic reactions of the patient to the preparation to obtain the side effects and allergic reaction ratio GM of the preparation q q and send the evaluation results to the comprehensive evaluation unit;
[0012] The preparation effectiveness evaluation unit is used to analyze and evaluate the preparation effectiveness in combination with the laboratory test results in the patient's electronic medical record data, and send the evaluation results to the comprehensive evaluation unit;
[0013] The comprehensive evaluation unit comprehensively evaluates the data in the drug combination evaluation unit, the preparation safety evaluation unit, and the preparation effectiveness evaluation unit, and sends the comprehensive evaluation results to the data visualization module;
[0014] The risk assessment module is used to assess risk issues arising during the preparation management and storage process, and send the assessment results to the data visualization module;
[0015] The data visualization module is used to display the results of the drug combination evaluation unit, the preparation safety evaluation unit, the preparation effectiveness evaluation unit and the comprehensive evaluation unit in the preparation evaluation module, as well as the risk assessment module.
[0016] As a preferred technical solution of the present invention, the specific steps of the combined medication evaluation unit for evaluating the interaction between multiple drugs are as follows:
[0017] A1. Read the patient's electronic medical record data and select all interactions between preparation q and drug i;
[0018] A2. Calculate the interaction probability between preparation q and drug i to obtain the mutual influence probability E q,i ;
[0019] A3. Calculate the probability E of the mutual influence of the preparations q q,i The average probability of interaction between preparations q is obtained The specific calculation expression is as follows:
[0020]
[0021] in, represents the average probability of interaction between agents q, E q,i represents the probability of mutual influence of preparations q, n represents the number of elements in N, ∑ i∈N * indicates the sum of the data in the data set N consisting of all drugs used in combination with preparation q in the electronic medical record data of the patient.
[0022] As a preferred technical solution of the present invention, the specific calculation expression of step A2 is as follows:
[0023]
[0024] Among them, M i The number of patients affected by preparation q and drug i, Q i Represents the total number of people who use preparation q in combination with drug i.
[0025] As a preferred technical solution of the present invention, the specific steps of the combined medication assessment unit for assessing the risk of adverse events are as follows:
[0026] B1. By reading the electronic medical records of the patients, the number of patients who were taking the combination drug containing the preparation q and the number of patients who were not taking the combination drug containing the preparation q or taking the drug alone corresponding to the patient's condition were screened out;
[0027] B2. Calculate the incidence rate of adverse events R of the two groups of patients respectively q and R \q , and the adverse event rate R q,\q .
[0028] As a preferred technical solution of the present invention, the calculation expressions of the adverse event incidence and the adverse event incidence ratio in step B2 are as follows:
[0029] The incidence of adverse events in combination with drug preparation q:
[0030]
[0031] The incidence of adverse events of combination or single drug use without preparation q:
[0032]
[0033] Adverse event rate:
[0034]
[0035] Among them, R q represents the incidence of adverse events of combination drugs containing preparation q, R\q Indicates the incidence of adverse events of combination or single drug use without the preparation q, FS q N represents the number of patients with adverse events when taking the combination drug containing preparation q. q indicates the total number of patients taking the combination drug containing preparation q, FS \q N represents the number of patients with adverse events when taking the drug in combination or alone without the drug q. \q represents the number of patients who received the drug in combination or alone without the drug q, R q,\q It represents the incidence rate of adverse events of preparation q relative to the combination of preparation q or the single medicine.
[0036] As a preferred technical solution of the present invention, the specific steps of the preparation safety assessment unit to assess the safety of the preparation based on the patient's side effects and allergic reactions to the preparation q are as follows:
[0037] C1. Screen out the number of patients who received combination medication containing preparation q or preparation q alone by reading the patient's electronic medical record data;
[0038] C2. Calculate the proportion of patients who experience side effects and allergic reactions to preparation q. The specific expression is as follows:
[0039]
[0040] Among them, GM q Indicates the proportion of side effects and allergic reactions caused by preparation q, N gm The number of patients who experienced side effects and allergic reactions to the drug q, NQ gm The number of patients who received the combination drug containing preparation q or preparation q alone.
[0041] As a preferred technical solution of the present invention, the preparation effectiveness evaluation unit calculates the efficacy ratio of preparation q and sends the calculation result to the comprehensive evaluation unit.
[0042] As a preferred technical solution of the present invention, the specific steps of the comprehensive evaluation unit for comprehensively evaluating the data in the combination medication evaluation unit, the preparation safety evaluation unit, and the preparation effectiveness evaluation unit are as follows:
[0043] D1. Set evaluation indicators for the corresponding estimated values in the combined medication evaluation unit and the preparation safety evaluation unit, and the initial value of the evaluation indicator is 0.
[0044] D2. Determine the thresholds of the calculated values in the combined medication assessment unit and the preparation safety assessment unit respectively. If they exceed the corresponding thresholds, add 1 to the value of the assessment index;
[0045] D3. If it is determined that the patient does not have an allergic reaction and the efficacy ratio calculated by the preparation effectiveness evaluation unit exceeds the corresponding threshold, the value of the evaluation index is reduced by 0.5.
[0046] As a preferred technical solution of the present invention, the steps of risk assessment by the risk assessment module are as follows:
[0047] E1. It is necessary to identify the risks that may occur during the storage and management of drug products, including human storage errors, equipment failures, and changes in environmental conditions;
[0048] E2. When the risk situation in step E1 occurs, the specific risk type is displayed through the data visualization module.
[0049] As a preferred technical solution of the present invention, the data visualization module respectively displays the specific values of the calculation results of the combination medication evaluation unit, the preparation safety evaluation unit, and the preparation effectiveness evaluation unit, as well as the evaluation indicators finally given by the comprehensive evaluation unit.
[0050] Compared with the prior art, the present invention provides a preparation evaluation system based on electronic medical record data, which has the following beneficial effects:
[0051] 1. The present invention evaluates a preparation in three aspects: combination medication evaluation unit, preparation safety evaluation unit, and preparation effectiveness evaluation unit, by combining the patient's electronic medical record data. At the same time, based on the evaluation of these three aspects, the comprehensive evaluation unit provides evaluation indicators for the preparation to provide data support for doctors to prescribe.
[0052] 2. The present invention reads the electronic medical records of patients to screen out the number of patients who are taking the combination drug containing the preparation q, and the number of patients who are not taking the combination drug containing the preparation q or taking the drug alone corresponding to the patient's symptoms, and calculates the incidence rate of adverse events R of the two groups of patients respectively. q and R \q , and the adverse event rate R q,\q , thereby ensuring the assessment of the risk of adverse events. BRIEF DESCRIPTION OF THE DRAWINGS
[0053] Figure 1 It is a schematic diagram of the system framework of the present invention. DETAILED DESCRIPTION
[0054] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0055] See also Figure 1 , a preparation evaluation system based on electronic medical record data, including a patient electronic medical record data collection module, a preparation evaluation module, a risk assessment module and a data visualization module;
[0056] The patient electronic medical record data collection module is used to collect the patient's electronic medical record data, including the patient's disease, drug prescription, medication history and laboratory test results. The patient electronic variable data collection module sends the collected data to the preparation evaluation module;
[0057] The preparation evaluation module includes the combination drug evaluation unit, preparation safety evaluation unit, preparation effectiveness evaluation unit and comprehensive evaluation unit;
[0058] The combined medication assessment unit is used to evaluate the interactions between multiple drugs when the patient needs to be treated with multiple drugs. The average probability of interaction between the preparations is obtained. The adverse event rate of the combination drug with preparation q relative to the combination drug without preparation q or the single drug was evaluated by R q,\q and send the evaluation results to the comprehensive evaluation unit;
[0059] The combination drug evaluation unit can also use survival analysis: If the survival data is being evaluated, survival analysis methods, such as the Kaplan-Meier curve and the Cox proportional hazard model, can be used to compare the survival curves and survival risks between the combination drug group and the monotherapy group.
[0060] Pharmacodynamic model establishment: Pharmacokinetic / Pharmacodynamic models (PK / PD models) can be used to evaluate the therapeutic effect and safety of drugs. These models can consider the absorption, distribution, metabolism and excretion of drugs, as well as factors such as drug-target binding and biological effects to supplement data
[0061] The preparation safety assessment unit is used to assess the safety of the preparation by measuring the side effects and allergic reactions of the patient to the preparation to obtain the side effects and allergic reaction ratio GM of the preparation q. q and send the evaluation results to the comprehensive evaluation unit;
[0062] The preparation effectiveness evaluation unit is used to analyze and evaluate the preparation effectiveness in combination with the laboratory test results in the patient's electronic medical record data, and send the evaluation results to the comprehensive evaluation unit;
[0063] The formulation effectiveness assessment unit can also supplement data through the following means
[0064] Medication regimen analysis: Use the drug prescription information and medication history recorded in the electronic medical record to evaluate the use and efficacy of in-hospital preparations. For example, the frequency of use of in-hospital preparations, dosage adjustments, and their association with treatment outcomes can be analyzed;
[0065] Analysis of laboratory test results: The safety and effectiveness of in-hospital preparations can be evaluated through laboratory test results in electronic medical records, such as blood indicators and biochemical indicators. For example, the changes in laboratory test results between patients using in-hospital preparations and patients using other treatment options can be analyzed;
[0066] Patient satisfaction survey: Through patient feedback information in electronic medical records, such as treatment experience, satisfaction with treatment effects, etc., the overall effect of in-hospital preparations can be evaluated. Patient feedback information can be collected through regular satisfaction surveys, and improvements can be made based on the feedback results.
[0067] The comprehensive evaluation unit conducts a comprehensive evaluation on the data in the combined medication evaluation unit, the preparation safety evaluation unit, and the preparation effectiveness evaluation unit, and sends the comprehensive evaluation results to the data visualization module;
[0068] The risk assessment module is used to assess the risk issues that arise during the preparation management and storage process, and send the assessment results to the data visualization module;
[0069] The data visualization module is used to display the results of the combination medication evaluation unit, the preparation safety evaluation unit, the preparation effectiveness evaluation unit and the comprehensive evaluation unit in the preparation evaluation module, as well as the risk assessment module.
[0070] Furthermore, the specific steps for the combined medication assessment unit to assess the interactions between multiple drugs are as follows:
[0071] A1. Read the patient's electronic medical record data and select all interactions between preparation q and drug i;
[0072] A2. Calculate the interaction probability between preparation q and drug i to obtain the mutual influence probability E q,i , the specific calculation expression of step A2 is as follows:
[0073]
[0074] Among them, M i The number of patients affected by preparation q and drug i, Q i represents the total number of people who use preparation q in combination with drug i;
[0075] A3. Calculate the probability E of the mutual influence of the preparations q q,i The average probability of interaction between preparations q is obtained The specific calculation expression is as follows:
[0076]
[0077] in, represents the average probability of interaction between agents q, E q,i represents the probability of mutual influence of preparations q, n represents the number of elements in N, ∑ i∈N * indicates the sum of the data in the data set N consisting of all drugs used in combination with preparation q in the electronic medical record data of the patient.
[0078] The specific steps for the combined medication assessment unit to assess the risk of adverse events are as follows:
[0079] B1. By reading the electronic medical records of the patients, the number of patients who were taking the combination drug containing the preparation q and the number of patients who were not taking the combination drug containing the preparation q or taking the drug alone corresponding to the patient's condition were screened out;
[0080] B2. Calculate the incidence rate of adverse events R of the two groups of patients respectively q and R \q , and the adverse event rate R q,\q , the calculation expressions of adverse event incidence and adverse event ratio are as follows:
[0081] The incidence of adverse events in combination with drug preparation q:
[0082]
[0083] The incidence of adverse events of combination or single drug use without preparation q:
[0084]
[0085] Adverse event rate:
[0086]
[0087] Among them, R q represents the incidence of adverse events of combination drugs containing preparation q, R \q Indicates the incidence of adverse events of combination or single drug use without the preparation q, FS q N represents the number of patients with adverse events when taking the combination drug containing preparation q. q indicates the total number of patients taking the combination drug containing preparation q, FS \q N represents the number of patients with adverse events when taking the drug in combination or alone without the drug q. \q represents the number of patients who received the drug in combination or alone without the drug q, R q,\qIt represents the incidence rate of adverse events of preparation q relative to the combination of preparation q or the single medicine.
[0088] Furthermore, the specific steps for the preparation safety assessment unit to assess the safety of the preparation based on the patient's side effects and allergic reactions to the preparation q are as follows:
[0089] C1. Screen out the number of patients who received combination medication containing preparation q or preparation q alone by reading the patient's electronic medical record data;
[0090] C2. Calculate the proportion of patients who experience side effects and allergic reactions to preparation q. The specific expression is as follows:
[0091]
[0092] Among them, GM q Indicates the proportion of side effects and allergic reactions caused by preparation q, N gm The number of patients who experienced side effects and allergic reactions to the drug q, NQ gm The number of patients who received the combination drug containing preparation q or preparation q alone.
[0093] The preparation effectiveness evaluation unit calculates the efficacy ratio of preparation q and sends the calculation result to the comprehensive evaluation unit, where the efficacy ratio ER AB The calculation expression is as follows:
[0094]
[0095] The efficacy ratio is a ratio used to compare the relative effectiveness of two or more treatment options. It calculates the ratio of the successful cure rate of one treatment option to the successful cure rate of another treatment option, and here the efficacy ratio of drug combination A relative to drug combination B is given.
[0096] Furthermore, the specific steps for the comprehensive evaluation unit to conduct a comprehensive evaluation of the data in the combination medication evaluation unit, the preparation safety evaluation unit, and the preparation effectiveness evaluation unit are as follows:
[0097] D1. Set evaluation indicators for the corresponding estimated values in the combined medication evaluation unit and the preparation safety evaluation unit, and the initial value of the evaluation indicator is 0.
[0098] D2. Determine the thresholds of the calculated values in the combined medication assessment unit and the preparation safety assessment unit respectively. If they exceed the corresponding thresholds, add 1 to the value of the assessment index;
[0099] D3. If it is determined that the patient does not have an allergic reaction and the therapeutic effect ratio calculated by the preparation effectiveness evaluation unit exceeds the corresponding threshold, the value of the evaluation index is reduced by 0.5. If the evaluation index is already 0, the operation of reducing 0.5 is not performed.
[0100] Through the above three steps, the preparation q is divided into the following levels, and the specific expressions are as follows:
[0101]
[0102] Among them, if the evaluation index is equal to 0, it means that the adverse events, side effects and allergic reactions of the drug in the current use of the drug are relatively small, and it is compatible with other drugs. The evaluation index is equal to 1, which means that the drug has a specific item of the corresponding adverse events, side effects, allergic reactions and compatibility with other drugs in the current use, which is exceeded, and can be displayed in the data visualization module. The evaluation index is equal to 0.5, which means that the drug has a specific item of the corresponding adverse events, side effects, allergic reactions and compatibility with other drugs in the use process, but the efficacy is excellent, and so on.
[0103] Furthermore, the steps of risk assessment in the risk assessment module are as follows:
[0104] E1. It is necessary to identify the risks that may occur during the storage and management of drug products, including human storage errors, equipment failures, and changes in environmental conditions;
[0105] E2. When the risk situation in step E1 occurs, the specific risk type is displayed through the data visualization module.
[0106] Furthermore, the data visualization module displays the specific values of the calculation results of the combined medication evaluation unit, the preparation safety evaluation unit, and the preparation effectiveness evaluation unit, as well as the evaluation indicators finally given by the comprehensive evaluation unit;
[0107] For the combined medication assessment unit:
[0108] To show the average probability of interaction among the preparations, intuitive charts such as bar charts or line charts can be used;
[0109] For the Drug Product Safety Assessment Unit:
[0110] Display adverse event rate R q and R \q As well as the corresponding number of patients with adverse events who did not contain the drug combination or took the drug alone, and the total number of patients who took the drug combination containing the drug combination, the safety assessment results can be intuitively presented in the form of dashboards or heat maps;
[0111] For the formulation effectiveness assessment unit:
[0112] To show the efficacy ratio of preparation q, you can use scatter plots or radar charts to show it intuitively.
[0113] The specific values of the evaluation indicators are displayed for the comprehensive evaluation unit, and can be ranked and output along with the indicators of all preparations.
[0114] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A drug product evaluation system based on electronic medical record data, characterized in that: It includes patient electronic medical record data collection module, formulation evaluation module, risk assessment module and data visualization module; The patient electronic medical record data collection module is used to collect the patient's electronic medical record data, including the patient's disease, drug prescription, medication history and laboratory test results, and the patient electronic variable data collection module sends the collected data to the preparation evaluation module; The preparation evaluation module includes a combination drug evaluation unit, a preparation safety evaluation unit, a preparation effectiveness evaluation unit and a comprehensive evaluation unit; The combined medication evaluation unit is used to evaluate the interactions between multiple drugs when a patient needs to be treated with multiple drugs. The adverse event rate of the combination drug with preparation q relative to the combination drug without preparation q or the single drug was evaluated by R q,\q and send the evaluation results to the comprehensive evaluation unit; The preparation safety assessment unit is used to assess the safety of the preparation by measuring the side effects and allergic reactions of the patient to the preparation to obtain the side effects and allergic reaction ratio GM of the preparation q q and send the evaluation results to the comprehensive evaluation unit; The preparation effectiveness evaluation unit is used to analyze and evaluate the preparation effectiveness in combination with the laboratory test results in the patient's electronic medical record data, and send the evaluation results to the comprehensive evaluation unit; The comprehensive evaluation unit comprehensively evaluates the data in the drug combination evaluation unit, the preparation safety evaluation unit, and the preparation effectiveness evaluation unit, and sends the comprehensive evaluation results to the data visualization module; The risk assessment module is used to assess risk issues arising during the preparation management and storage process, and send the assessment results to the data visualization module; The data visualization module is used to display the results of the drug combination evaluation unit, the preparation safety evaluation unit, the preparation effectiveness evaluation unit and the comprehensive evaluation unit in the preparation evaluation module, as well as the risk assessment module.
2. A drug preparation evaluation system based on electronic medical record data according to claim 1, characterized in that: The specific steps of the combined medication evaluation unit for evaluating the interactions between multiple drugs are as follows: A1. Read the patient's electronic medical record data and select all interactions between preparation q and drug i; A2. Calculate the interaction probability between preparation q and drug i to obtain the mutual influence probability E q,i ; A3. Calculate the probability E of the mutual influence of the preparations q q,i The average probability of interaction between preparations q is obtained The specific calculation expression is as follows: in, represents the average probability of interaction between agents q, E q,i represents the probability of mutual influence of preparations q, n represents the number of elements in N, ∑ i∈N * indicates the sum of the data in the data set N consisting of all drugs used in combination with preparation q in the electronic medical record data of the patient.
3. A drug preparation evaluation system based on electronic medical record data according to claim 2, characterized in that: The specific calculation expression of step A2 is as follows: Among them, M i The number of patients affected by preparation q and drug i, Q i Represents the total number of people who use preparation q in combination with drug i.
4. A drug product evaluation system based on electronic medical record data according to claim 3, characterized in that: The specific steps of the combined medication assessment unit for assessing the risk of adverse events are as follows: B1. By reading the electronic medical records of the patients, the number of patients who were taking the combination drug containing the preparation q and the number of patients who were not taking the combination drug containing the preparation q or taking the drug alone corresponding to the patient's condition were screened out; B2. Calculate the incidence rate of adverse events R of the two groups of patients respectively q and R \q , and the adverse event rate R q,\q .
5. A drug preparation evaluation system based on electronic medical record data according to claim 4, characterized in that: The calculation expressions of the adverse event incidence and adverse event incidence ratio in step B2 are as follows: The incidence of adverse events in combination with drug preparation q: The incidence of adverse events of combination or single drug use without preparation q: Adverse event rate: Among them, R q represents the incidence of adverse events of combination drugs containing preparation q, R \q Indicates the incidence of adverse events of combination or single drug use without the preparation q, FS q N represents the number of patients with adverse events when taking the combination drug containing preparation q. q indicates the total number of patients taking the combination drug containing preparation q, FS \q N represents the number of patients with adverse events when taking the drug in combination or alone without the drug q. \q represents the number of patients who received the drug in combination or alone without the drug q, R q,\q It represents the incidence rate of adverse events of preparation q relative to the combination of preparation q or the single medicine.
6. The drug product evaluation system based on electronic medical record data according to claim 1, characterized in that: The specific steps of the preparation safety assessment unit to assess the safety of the preparation based on the patient's side effects and allergic reactions to the preparation q are as follows: C1. Screen out the number of patients who received combination medication containing preparation q or preparation q alone by reading the patient's electronic medical record data; C2. Calculate the proportion of patients who experience side effects and allergic reactions to preparation q. The specific expression is as follows: Among them, GM q Indicates the proportion of side effects and allergic reactions caused by preparation q, N gm The number of patients who experienced side effects and allergic reactions to the drug q, NQ gm The number of patients who received the combination drug containing preparation q or preparation q alone.
7. The drug product evaluation system based on electronic medical record data according to claim 1, characterized in that: The preparation effectiveness evaluation unit calculates the efficacy ratio of preparation q and sends the calculation result to the comprehensive evaluation unit.
8. The drug preparation evaluation system based on electronic medical record data according to claim 1, characterized in that: The specific steps of the comprehensive evaluation unit for comprehensively evaluating the data in the combination medication evaluation unit, the preparation safety evaluation unit, and the preparation effectiveness evaluation unit are as follows: D1. Set evaluation indicators for the corresponding estimated values in the combined medication evaluation unit and the preparation safety evaluation unit, and the initial value of the evaluation indicator is 0; D2. Determine the thresholds of the calculated values in the combined medication assessment unit and the preparation safety assessment unit respectively. If they exceed the corresponding thresholds, add 1 to the value of the assessment index; D3. If it is determined that the patient does not have an allergic reaction and the efficacy ratio calculated by the preparation effectiveness evaluation unit exceeds the corresponding threshold, the value of the evaluation index is reduced by 0.
5.
9. A drug product evaluation system based on electronic medical record data according to claim 8, characterized in that: The steps of risk assessment performed by the risk assessment module are as follows: E1. It is necessary to identify the risks that may occur during the storage and management of drug products, including human storage errors, equipment failures, and changes in environmental conditions; E2. When the risk situation in step E1 occurs, the specific risk type is displayed through the data visualization module.
10. A drug product evaluation system based on electronic medical record data according to claim 9, characterized in that: The data visualization module respectively displays the specific values of the calculation results of the combination medication evaluation unit, the preparation safety evaluation unit, and the preparation effectiveness evaluation unit, as well as the evaluation indicators finally given by the comprehensive evaluation unit.
Citation Information
Patent Citations
Clinical medication decision support system
CN102737165A
Systems and methods for clinical decision support
CN105144179A
Electronic medical record big data-based clinical reasonable drug use risk assessment method
CN107341345A
Medication recommendation method and device based on artificial intelligence, equipment and a storage medium
CN111667890A
Major disease medical insurance drug auditing and drug treatment management system
CN113488134A
Cited By
Medical medicine curative effect evaluation method based on big data analysis of electronic health record
CN121075701A
